• LAST PRICE
    0.0128
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0115 / 0.0128
  • Day Range
    Low 0.0115
    High 0.0140
  • 52 Week Range
    Low 0.0016
    High 0.0310
  • Volume
    465,300
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.0111
TimeVolumeCUBT
09:42 ET10000.0115
10:04 ET200000.0125
10:45 ET1000000.0129
11:41 ET100000.0129
12:14 ET15000.01334
12:21 ET50000.014
12:48 ET4000.01275
12:51 ET1125000.0125
02:16 ET249000.0138
02:30 ET500000.01275
02:34 ET589500.013
03:14 ET660500.013
03:15 ET150000.01275
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCUBT
Curative Biotechnology Inc
8.0M
-1.2x
---
United StatesCNTB
Connect Biopharma Holdings Ltd
57.8M
0.0x
---
United StatesKZIA
Kazia Therapeutics Ltd
12.3M
-0.5x
---
United StatesENZN
Enzon Pharmaceuticals Inc
7.8M
-32.3x
---
United StatesGRTX
Galera Therapeutics Inc
7.7M
-0.1x
---
United StatesBCEL
Atreca Inc
8.5M
-0.1x
---
As of 2023-12-04

Company Information

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Contact Information

Headquarters
1825 Nw Corporate Blvd., Suite 110BOCA RATON, FL, United States 33431
Phone
561-907-8990
Fax
---

Executives

Chairman of the Board, President
Paul Michaels
Chief Executive Officer, Chief Financial Officer, General Counsel
Richard Garr
Director
Michael Fish
Director, Chief Strategy Officer
Barry Ginsberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.0M
Revenue (TTM)
$0.00
Shares Outstanding
628.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.01
Book Value
$0.00
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.